Search

Displaying results 141 - 150 of 5935 in total
  1. Drug

    Patisiran

    go.drugbank.com/drugs/DB14582
    Approved

    It is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced. … The approval for Onpattro was granted to Alnylam Pharmaceuticals, Inc. in August of 2018. Onpattro has been granted Fast Track, Priority Review and Breakthrough Therapy, and Orphan Drug designations.

  2. Target

    Baculoviral IAP repeat-containing protein 5

    go.drugbank.com/bio_entities/BE0003408
    TargetHumans

    Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis (PubMed:20627126, PubMed:21364656, PubMed:25778398, PubMed:28218735, PubMed:9859993). Component of a chromosome passage protein complex (CP...

    Polypeptides: Baculoviral IAP repeat-containing protein 5
  3. Target

    Baculoviral IAP repeat-containing protein 7

    go.drugbank.com/bio_entities/BE0010707
    TargetHumans

    Apoptotic regulator capable of exerting proapoptotic and anti-apoptotic activities and plays crucial roles in apoptosis, cell proliferation, and cell cycle control (PubMed:11024045, PubMed:11084335, PubMed:11162435, PubMed:16729033, PubM...

    Polypeptides: Baculoviral IAP repeat-containing protein 7
  4. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    In September 2015, lusutrombopag received its first global approval in Japan to reduce the need for platelet transfusion in adults with chronic liver disease and thrombocytopenia who are schedule to undergo … In two randomized, double-blind, placebo-controlled trials, patients with chronic liver disease and severe thrombocytopenia who were undergoing an invasive procedure with a platelet count less than 50

  5. Drug

    Belantamab mafodotin

    go.drugbank.com/drugs/DB15719
    ApprovedInvestigationalWithdrawn

    [L53673] Later that year in October of 2025, belantamab was granded full approval by the FDA for the a similar indication to the Health Canada one. [L54331] … In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program.

  6. Drug

    Imelasomeran

    go.drugbank.com/drugs/DB17090
    ApprovedInvestigational

    Imelasomeran was first approved in Canada on September 1, 2022, as one-half of Moderna's Spikevax Bivalent COVID-19 mRNA vaccine.

  7. Drug

    Selinexor

    go.drugbank.com/drugs/DB11942
    ApprovedInvestigational

    least one prior therapy. … [L10145] The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at

  8. Drug

    Coagulation Factor IX Human

    go.drugbank.com/drugs/DB13152
    ApprovedInvestigational

    Factor IX (or Christmas factor) is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes hemophilia B.

  9. Drug

    Polysorbate 80

    go.drugbank.com/drugs/DB11063
    ApprovedInvestigational

    [L1852] A solubilizing agent acts as a surfactant and increases the solubility of one agent in another. … A substance that would not normally dissolve in a particular solution is able to dissolve with the use of a solubilizing agent.

  10. Drug

    Sodium phosphate, monobasic, unspecified form

    go.drugbank.com/drugs/DB14503
    Approved

    Mixtures: Care One Enema, Ready-to-Use